On Friday Reliant Pharmaceuticals launched a bid to raise as much as $400 million in an IPO. About half of that could go to pay off debt and the rest could be used for a variety of corporate expenses, including new acquisitions. Liberty Corner, NJ-based Reliant has four cardiovascular therapies on the market in the U.S. Reliant's development strategy focuses on in-licensing mid- to late-stage products in order to reduce the risk of development. The company was founded in 1999.
- here's the release on the IPO
Reliant pulls IPO. Report